EP Patent

EP3524247A1 — Rapidly disintegrating formulations and methods of use

Assigned to Impax Laboratories LLC · Expires 2019-08-14 · 7y expired

What this patent protects

The invention relates to a rapidly disintegrating oral dosage form that contains a drug/polymer solid solution and methods of using the oral dosage form.

USPTO Abstract

The invention relates to a rapidly disintegrating oral dosage form that contains a drug/polymer solid solution and methods of using the oral dosage form.

Drugs covered by this patent

apomorphine-hydrochloride (APOMORPHINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP3524247A1
Jurisdiction: EP
Classification: —
Expires: 2019-08-14
Drug substance claim: No
Drug product claim: No
Assignee: Impax Laboratories LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.